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H I V / A I D SM A J O R A R T I C L E
Changes Over Time in Risk Factors for
Cardiovascular Disease and Use of Lipid-Lowering
Drugs in HIV-Infected Individuals and Impact on
Myocardial Infarction
Data Collection on Adverse Events of Anti-HIV Drugs Study Groupa
Background. Because of the known relationship between exposure to combination antiretroviral therapy and
cardiovascular disease (CVD), it has become increasingly important to intervene against risk of CVD in human
immunodeficiency virus (HIV)–infected patients. We evaluated changes in risk factors for CVD and the use of
lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of
myocardial infarction.
Methods. The Data Collection on Adverse Events of Anti-HIV Drugs Study is a collaboration of 11 cohorts
of HIV-infected patients that included follow-up for 33,389 HIV-infected patients from December 1999 through
February 2006.
Results. The proportion of patients at high risk of CVD increased from 35.3% during 1999–2000 to 41.3%
during 2005–2006. Of 28,985 patients, 2801 (9.7%) initiated lipid-lowering therapy; initiation of lipid-lowering
therapy was more common for those with abnormal lipid values and those with traditional risk factors for CVD
(male sex, older age, higher body mass index [calculated as the weight in kilograms divided by the square of the
height in meters], family and personal history of CVD, and diabetes mellitus). After controlling for these, use of
lipid-lowering drugs became relatively less common over time. The incidence of myocardial infarction (0.32 cases
per 100 person-years [PY]; 95% confidence interval [CI], 0.29–0.35 cases per 100 PY) appeared to remain stable.
However, after controlling for changes in risk factors for CVD, the rate decreased over time (relative rate in 2003
[compared with 1999–2000], 0.73 cases per 100 PY [95% CI, 0.50–1.05 cases per 100 PY]; in 2004, 0.64 cases per
100 PY [95% CI, 0.44–0.94 cases per 100 PY]; in 2005–2006, 0.36 cases per 100 PY [95% CI, 0.24–0.56 cases per
100 PY]). Further adjustment for lipid levels attenuated the relative rates towards unity (relative rate in 2003
[compared with 1999–2000], 1.06 cases per 100 PY [95% CI, 0.63–1.77 cases per 100 PY]; in 2004, 1.02 cases per
100 PY [95% CI, 0.61–1.71 cases per 100 PY]; in 2005–2006, 0.63 cases per 100 PY [95% CI, 0.36–1.09 cases per
100 PY]).
Conclusions. Although the CVD risk profile among patients in the Data Collection on Adverse Events of Anti-
HIV Drugs Study has decreased since 1999, rates have remained relatively stable, possibly as a result of a more
aggressive approach towards managing the risk of CVD.
A number of studies have reported a link between com-
bination antiretroviral therapy (cART) and cardiovas-
cular disease (CVD) in HIV-infected individuals [1–8].
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The use of cART is, however, only 1 of many factors
that contribute to the development of CVD in HIV-
infected individuals. Traditional risk factors for CVD,
including male sex, older age, and cigarette smoking,
are prevalent in this group [8]. Because HIV-infected
individuals are surviving longer, they may experience
clinical events consistent with those experienced by an
aging population [9, 10]. Thus, attempts to reduce the
a Members of the study group are listed at the end of the text.
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risk of CVD have taken on greater importance in recent years.
The Data Collection on Adverse Events of Anti-HIV Drugs
(DAD) study has the unique ability to monitor risk factors for
CVD in a large and geographically diverse population of HIV-
infected individuals over time. The aim of the present analysis
was to describe changes in CVD risk factors and the use of
lipid-lowering drugs from December 1999 through February
2006 in DAD participants and to assess the impact of any
changes on the incidence of myocardial infarction (MI).
METHODS
The DAD study is a large, observational study formed by the
collaboration of 11 cohorts of HIV-infected patients. The pri-
mary aim of the study is to establish whether the use of cART
is associated with an increased risk of CVD. The 11 cohorts
currently contribute data on 33,389 HIV-infected patients mon-
itored at 212 clinics in Europe, the United States, and Australia
[8, 11]. Patients were all receiving active follow-up at the time
of enrollment and were observed prospectively, with data ob-
tained during regular outpatient visits. The standardized data
set includes information on sociodemographic characteristics;
clinical AIDS events and deaths; known risk factors for CVD;
CD4 cell count; HIV RNA level; total cholesterol, high-density
lipoprotein (HDL) cholesterol, and triglyceride levels; antiret-
roviral treatment history; and information on the use of lipid-
lowering therapy, platelet aggregation inhibitors, angiotensin
converting enzyme inhibitors, and antihypertensive, antidi-
abetic, or anabolic steroid therapy. All data are transferred to
the coordinating center as anonymous computerized files and
are merged into a central dataset. Detailed information re-
garding study end points (CVD and death) is provided in real
time; each end point is validated and coded centrally. The DAD
study has appropriate ethical committee approval from each
participating country.
Statistical Analyses
Changes in risk factors over time. We considered 6 calendar
intervals: 1999–2000, 2001, 2002, 2003, 2004, and 2005–2006.
Patients undergoing follow-up in the DAD study in each in-
terval were classified according to their risk factor status at the
end of the interval, and patient characteristics were compared
using x2 tests and analysis of variance, considering patients
undergoing follow-up in each interval as independent groups.
The definition of a “high-risk” individual, based on the Na-
tional Cholesterol Education Program guidelines [12], included
individuals with a previous episode of CVD (MI, stroke, or an
invasive cardiovascular procedure), diabetes mellitus, or 2 of
the following risk factors: older age (45 years for men and
55 years for women), current smoker, family history of CVD,
the presence of hypertension (systolic blood pressure, 1140 mm
Hg; diastolic blood pressure, 190 mm Hg; or use of antihy-
pertensive drugs and/or angiotensin converting enzyme inhib-
itors), or dyslipidaemia (total cholesterol level, 6.2 mmol/L;
HDL cholesterol level, 0.9 mmol/L; total cholesterol:HDL
cholesterol ratio, 6.5; or the use of lipid-lowering drugs). All
lipid measurements were considered, regardless of fasting
status.
Use of lipid-lowering drugs. Poisson regression (GEN-
MOD procedure in SAS, version 9 [SAS Institute]) identified
factors associated with the initiation of lipid-lowering drugs,
with the period of follow-up considered to be from the time
of entry in the DAD study to the date of initiation of lipid-
lowering drugs, the date of death, the patient’s last clinic visit,
or 1 February 2006 (whichever occurred first). Each individual’s
follow-up time was split into a series of 1-month periods, and
their demographic characteristics, risk factors for CVD, and
lipid levels were evaluated at the start of each period. The factors
included in this analysis were calendar period, sex, age, HIV
risk group (men who have sex with men, injection drug users,
heterosexual persons, or other), ethnicity (white, black African,
other known, or missing), body mass index (calculated as the
weight in kilograms divided by the square of the height in
meters), smoking status (current smoker, ex-smoker, never
smoker, or unknown), family history of CVD, diagnosis of
diabetes mellitus, a previous cardiovascular event, cumulative
exposure to cART, and the patient’s most recent CD4 cell count,
HIV RNA level, total cholesterol level, HDL cholesterol level,
and triglyceride level. Although high-risk status was considered
as a factor in univariable analyses, it was not included in the
multivariable analyses because of the strong collinearity with
other CVD risk factors. A total of 1348 patients who were
already receiving lipid-lowering drugs at enrollment and 3056
patients from 1 cohort that did not provide this information
were excluded. Because fibrates and statins may have different
effects on lipid parameters, the multivariable analyses were re-
peated without adjusting for the latest values of each lipid
parameter. All analyses were adjusted for study cohort. Missing
data on risk factors were generally incorporated through the
inclusion of “unknown” categories for each variable. When
lipid measurements were missing at entry in the DAD study,
patient follow-up for analyses that included time-updated lipid
levels was left-truncated until the time of the patient’s first
available lipid measurement.
Changes in the incidence of MI. We investigated trends
over time in the incidence of MI and whether these could be
explained by changes in the CVD risk profiles of patients. The
analysis was similar to previous analyses performed in the DAD
study [8] and used Poisson regression, as described above. Only
the first MI during prospective follow-up was included in the
analyses; thus, patient follow-up was censored once an MI had
occurred. We considered the relationship between the incidence
of MI and calendar period, as well as the relationship between
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Table 1. Demographic characteristics of and risk factors for cardiovascular disease (CVD) in patients undergoing follow-up in
the Data Collection on Adverse Events of Anti-HIV Drugs Study in the 6 calendar periods.
Variable
Calendar period
1999–2000 2001 2002 2003 2004 2005–2006
No. of patients who underwent follow-up 21,483 23,705 26,613 28,400 28,495 25,613
Male sex 16,203 (75.4) 17,922 (75.6) 19,906 (74.8) 21,092 (74.3) 21,027 (73.8) 18,857 (73.6)
Age, median years (IQR) 39 (35–45) 40 (35–46) 40 (36–47) 41 (36–48) 42 (37–48) 43 (38–49)
Risk group
Men who have sex with men 9487 (44.2) 10,638 (44.9) 11,841 (44.5) 12,554 (44.2) 12,472 (43.8) 11,244 (43.9)
Injection drug user 4526 (21.1) 4673 (19.7) 4765 (17.9) 4779 (16.8) 4656 (16.3) 4135 (16.1)
Heterosexual 5769 (26.9) 6277 (26.5) 7602 (28.6) 8450 (29.8) 8808 (30.9) 7903 (30.9)
Other or unknown 1701 (7.9) 2117 (8.9) 2405 (9.0) 2617 (9.2) 2559 (9.0) 2331 (9.1)
Ethnicity
White 10,615 (49.4) 11,260 (47.5) 11,703 (44.0) 12,130 (42.7) 12,544 (44.0) 11,170 (43.6)
Black African 2027 (9.4) 2451 (10.3) 2632 (9.9) 2761 (9.7) 2794 (9.8) 2494 (9.7)
Other 610 (2.8) 751 (3.2) 766 (2.9) 790 (2.8) 847 (3.0) 770 (3.0)
Not known 8231 (38.3) 9243 (39.0) 11,512 (43.3) 12,719 (44.8) 12,310 (43.2) 11,179 (43.7)
Risk factor for CVD
Older agea 5375 (25.0) 6515 (27.5) 7672 (28.8) 8817 (31.1) 9520 (33.4) 9529 (37.2)
Current smokerb 8508 (47.5) 9307 (47.7) 9419 (44.5) 8772 (39.5) 8800 (38.7) 7868 (38.4)
Previous CVD 418 (2.0) 543 (2.3) 648 (2.4) 749 (2.6) 825 (2.9) 814 (3.2)
Diabetes mellitus 807 (3.8) 1005 (4.2) 1180 (4.4) 1376 (4.9) 1406 (4.9) 1321 (5.2)
Family history of CVD 1525 (7.1) 1732 (7.3) 1983 (7.5) 2082 (7.3) 2225 (7.8) 2142 (8.4)
Hypertension 2237 (10.4) 2881 (12.2) 3479 (13.1) 4091 (14.4) 4853 (17.0) 4792 (18.7)
Received lipid-lowering therapyc 1235 (6.3) 1885 (8.9) 2399 (10.0) 2918 (11.3) 3395 (13.0) 3527 (15.1)
Dyslipidaemia 7363 (34.3) 8678 (36.6) 9344 (35.1) 10,006 (35.2) 10,353 (36.3) 9098 (35.5)
Underwent an invasive procedure for CVDd
Prior to myocardial infarction or stroke 79 (0.4) 96 (0.4) 116 (0.4) 139 (0.5) 158 (0.6) 157 (0.6)
After myocardial infarction or stroke 85 (0.4) 128 (0.5) 163 (0.6) 208 (0.7) 249 (0.9) 256 (1.0)
High-risk individuale 7576 (35.3) 9045 (38.2) 9896 (37.2) 10,483 (36.9) 11,206 (39.3) 10,569 (41.3)
NOTE. Data are no. (%) of patients, unless otherwise indicated. All comparisons were statistically significant ( ).P ! .001
a Men aged 45 years and women aged 55 years were considered to be of older age.
b Based on those individuals for whom this information was available (17,931 in 1999–2000, 19,529 in 2001, 21,180 in 2002, 22,224 in 2003, 22,766 in
2004, and 20,479 in 2005–2006).
c Based on information from 10 of the 11 cohorts.
d Invasive procedures (coronary artery bypass, carotic endarterectomy, or angioplasty/stenting) were considered to be prior to myocardial infarction or
stroke if they occurred in individuals who did not experience a myocardial infarction or stroke or in those who experienced one of these events, if the
procedure occurred at least 1 month prior to the event.
e High-risk individuals were those who had previous CVD, had received a diagnosis of diabetes mellitus, or had 2 risk factors for CVD (see Methods).
the incidence of MI and cumulative exposure to protease in-
hibitor and nonnucleoside reverse-transcriptase inhibitor ther-
apy. These analyses were adjusted for (1) each individual’s risk
factor status at entry into the DAD study (a fixed covariate
analysis), (2) changes in known risk factors (except lipid levels)
over the course of the study (age, body mass index, family
history of CVD, smoking status, and previous CVD; a time-
updated analysis), and (3) these changes in addition to further
adjustment for the latest lipid measurements as time-dependent
covariates. The rationale for separating out the adjustment for
lipid levels from other CVD risk factors is that lipid levels are
known to be influenced by antiretroviral therapy and lipid-
lowering drugs. The use of lipid-lowering drugs was not spe-
cifically included as a covariate, because it was anticipated that
any effect of these drugs would act primarily through changes
in an individual’s lipid values. All analyses were also adjusted
for cohort, risk group, and ethnicity.
RESULTS
Changes in risk factors over time. Risk factor profiles gen-
erally worsened over time, with increases in the proportions of
patients who were older, had a history of CVD, had received
a diagnosis of diabetes mellitus, had a family history of CVD,
had hypertension, or had undergone an invasive cardiovascular
procedure following an MI or stroke (table 1). At the same
time, there was an increase in the proportions of patients re-
ceiving lipid-lowering therapy and undergoing invasive cardio-
vascular procedures prior to an MI or stroke. There was a
reduction in the prevalence of smoking from 2003 onwards.
Changes in risk factors were generally more pronounced in
men than in women, with the proportions of men and women
at high risk of CVD increasing from 40.1% during 1999–2000
to 47.8% during 2005–2006 and from 20.4% to 22.9% during
the same periods, respectively. In contrast, the proportion of
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patients at high risk of CVD remained relatively stable among
those who were both younger (from 22.4% to 22.7%) and older
(from 73.8% to 72.6%).
Use of lipid-lowering drugs. A total of 28,985 patients from
10 of the 11 cohorts were not receiving lipid-lowering drugs
at study entry; 2801 (9.7%) of these patients started receiving
lipid-lowering drugs during the follow-up period. At the time
of initiation of lipid-lowering therapy, 2418 patients (86.3%)
had at least 1 abnormal lipid measurement (1656 [59.1%] had
a total cholesterol level6.2 mmol/L, 689 [24.6%] had an HDL
cholesterol level 0.9 mmol/L, and 1907 [68.1%] had a tri-
glyceride level 2.3 mmol/L), and 237 (8.5%) had experienced
a prior cardiovascular event.
As expected, the rate of initiation of lipid-lowering drugs
was substantially higher among those with higher total cho-
lesterol levels (ranging from 0.59 episodes per 100 person-years
[PY] among those with a total cholesterol level !3.9 mmol/L
to 10.91 episodes per 100 PY among those with a total cho-
lesterol level 6.4 mmol/L), among those with higher triglyc-
eride levels (ranging from 0.49 episodes per 100 PY among
those with a triglyceride level !0.9 mmol/L to 10.10 episodes
per 100 PY among those with a triglyceride level 3.6 mmol/
L), and among those with lower HDL cholesterol levels (ranging
from 1.86 episodes per 100 PY among those with an HDL
cholesterol level 1.52 mmol/L to 3.63 episodes per 100 PY
among those with an HDL cholesterol level !0.8 mmol/L).
High-risk individuals had a significantly higher rate of initiation
of lipid-lowering drugs (4.94 episodes per 100 PY), compared
with low-risk individuals (1.17 episodes per 100 PY; Pp
). Other factors associated with a more rapid initiation of.001
lipid-lowering therapy in univariable analyses were male sex,
older age, higher body mass index, men who have sex with
men (risk for HIV infection), white race, family or personal
history of CVD, diagnosis of diabetes mellitus, increased ex-
posure to cART, and earlier calendar year, whereas the rate of
initiation of lipid-lowering therapy was lower among smokers
(either current or ex-smokers).
In multivariable analyses that included the latest measure-
ment of lipid parameters (table 2), the rate of starting lipid-
lowering therapy was higher among men, those with a higher
body mass index, those with a family history of CVD, those
with diabetes mellitus, those who experienced a previous car-
diovascular event, and older individuals. Compared with men
who have sex with men, injection drug users were less likely
to start lipid-lowering therapy. The rate of starting lipid-low-
ering therapy increased by 52% per 1 mmol/L higher total
cholesterol level and by 10% per 1 mmol/L higher triglyceride
level and was reduced by 33% per 1 mmol/L higher HDL
cholesterol level. The rate of starting lipid-lowering therapy
increased by 8% per year of exposure to cART. After controlling
for these factors, there was a reduced rate of starting lipid-
lowering therapy from 2002 onwards. Although statistically sig-
nificant in univariable analyses, smoking status did not remain
associated with the use of lipid-lowering therapy and was not
included in the final multivariable model. There was no evi-
dence that the relationship between the lipid levels and initi-
ation of lipid-lowering therapy changed over time. As shown
in table 2, analyses that did not incorporate the lipid levels
provided similar results, although the effect of each risk factor
was generally stronger in these analyses.
Changes in the incidence of MI over time. By 1 February
2006, a total of 445 episodes of MI had been reported over
137,310 PY of follow-up (median follow-up time, 4.5 years;
event rate, 0.32 episodes per 100 PY; 95% CI, 0.29–0.35). The
event rates in the 6 calendar periods (1999–2000, 2001, 2002,
2003, 2004, and 2005–2006) were 0.32 episodes per 100 PY
(95% CI, 0.23–0.41), 0.43 episodes per 100 PY (95% CI, 0.34–
0.51), 0.31 episodes per 100 PY (95% CI, 0.24–0.38), 0.34 ep-
isodes per 100 PY (95% CI, 0.27–0.41), 0.33 episodes per 100
PY (95% CI, 0.26–0.40), and 0.22 episodes per 100 PY (95%
CI, 0.16–0.28), respectively. After adjusting for the baseline de-
mographic and CVD risk factor status of patients at enrollment
in the DAD study, there was a small but generally non–statis-
tically significant (except for in 2005–2006) decrease in the MI
rate over time (table 3). Adjustment for changes in known risk
factors for MI (excluding lipid values) over the study period
resulted in a clearer decrease in the rate of MI over time (table
3). This suggests that, were it not for the detrimental changes
in the risk factor profile (largely driven by age) of participating
patients over time (which would be expected to cause an in-
crease in the risk of MI in this group), a decrease in incidence
would have been seen. Importantly, when the analyses were
adjusted for changes in each patient’s updated lipid levels, as
well as their other CVD risk factors, the reduction in the rate
of MI from 2003 onwards became non–statistically significant,
with relative rates that were close to unity (table 3). These
findings suggest that any changes in MI incidence in this cohort
over time can largely be attributed to changes in the lipid levels
in patients in the cohort.
CONCLUSIONS
Since 1999, there has been a general worsening of the CVD
risk factor profile among HIV-infected individuals in the DAD
study. Individuals have aged, and possibly as a result, some
have developed diabetes mellitus, hypertension, and/or dysli-
pidaemia or have undergone invasive procedures for CVD.
There has been an encouraging decrease in the proportion of
smokers since 2002, and individuals (particularly those at high
risk of CVD) are more likely to be receiving lipid-lowering
drugs. This targeted use of interventions among those at high
risk of CVD has undoubtedly had a positive impact on the
overall incidence of MI, largely as a result of improved lipid
HIV/AIDS • CID 2008:46 (1 April) • 1105
Table 2. Estimated relative rate of factors independently associated with initiation of lipid-lowering therapy.
Variable
Model including
lipid parameters
Model excluding
lipid parameters
Relative rate (95% CI) P Relative rate (95% CI) P
Male sex 1.19 (1.04–1.37) .01 1.43 (1.27–1.61) !.001
Age (per 5 years older) 1.14 (1.12–1.17) !.001 1.18 (1.15–1.20) !.001
BMI
!18.0 0.72 (0.53–0.97) .01 0.70 (0.53–0.92) !.001
18.0–26.0 1 1
26.1–30.0 1.04 (0.92–1.18) 1.29 (1.16–1.44)
30.1 1.28 (1.05–1.57) 1.38 (1.14–1.66)
Not known 0.93 (0.83–1.05) 1.00 (0.90–1.10)
Risk group
Men who have sex with men 1 !.001 1 !.001
Injection drug user 0.64 (0.55–0.75) 0.46 (0.40–0.53)
Heterosexual 0.94 (0.85–1.06) 0.94 (0.85–1.04)
Other/unknown 1.02 (0.86–1.20) 0.91 (0.79–1.06)
Family history of CVD 1.20 (1.05–1.38) .01 1.34 (1.18–1.51) !.001
Diagnosis of diabetes mellitus 1.47 (1.28–1.70) !.001 1.81 (1.59–2.07) !.001
Previous cardiovascular event 3.47 (2.96–4.07) !.001 3.64 (3.15–4.21) !.001
Cumulative exposure to cART (per year) 1.08 (1.06–1.10) !.001 1.16 (1.14–1.18) !.001
Calendar period
1999–2000 1 !.001 1 !.001
2001 1.03 (0.88–1.21) 0.98 (0.86–1.12)
2002 0.98 (0.83–1.16) 0.76 (0.66–0.87)
2003 0.91 (0.77–1.08) 0.68 (0.59–0.78)
2004 0.80 (0.67–0.95) 0.52 (0.45–0.61)
2005–2006 0.59 (0.49–0.71) 0.36 (0.31–0.43)
Latest TC level (per mmol/L higher)a 1.52 (1.49–1.55) !.001 NA
Latest HDLC level (per mmol/L lower)a 0.67 (0.59–0.74) !.001 NA
Latest TG level (per mmol/L higher)a 1.10 (1.08–1.11) !.001 NA
NOTE. Analyses include data for 28,985 patients from 10 of the 11 cohorts. BMI, body mass index (calculated as the weight in
kilograms divided by the square of the height in meters); cART, combination antiretroviral therapy; CVD, cardiovascular disease; HDLC,
high-density lipoprotein cholesterol; NA, not applicable; TC, total cholesterol; TG, triglyceride.
a Patients without baseline lipid measurements were excluded from the risk set for these analyses until the date of their first available
lipid measurement.
profiles among these individuals. However, any decreases in MI
incidence attributable to improved patient treatment appear to
have been offset by a gradual worsening of the CVD risk profile
of the cohort as patients have aged. Thus, overall, we have not
seen as great a reduction in the incidence of MI over time as
might have been expected.
Although there are some guidelines for the use of lipid-
lowering therapy for individuals with HIV infection [13], evi-
dence to support their effectiveness in the prevention of CVD
in this population is lacking. The overall conclusions regarding
the use of lipid-lowering therapy have often been confusing
[14–16]. Our results from this current analysis suggest that
clinicians have become increasingly willing to initiate lipid-
lowering therapy for patients with abnormal lipid levels, dia-
betes, and other risk factors for CVD, although other work
from our group [17] suggests that the use of lipid-lowering
therapy in those with existing CVD remains suboptimal. In-
terestingly, the peak of initiation of lipid-lowering therapy oc-
curred in 2001, with a subsequent decrease thereafter, possibly
reflecting an early rapid uptake of these drugs among those
with the greatest need for cART after the initial reports of a
relationship between cART and MI and/or possible underuse
of these drugs in later years. Unfortunately, the study did not
collect information regarding the class of lipid-lowering drugs
used (e.g., fibrates or statins). Because these different drug clas-
ses may have different effects on lipid levels, models that include
these variables may be difficult to interpret. However, exclusion
of the lipid parameters from these models led to similar con-
clusions regarding the other parameters in the model. It should
be noted that injection drug users were less likely to receive
lipid-lowering therapy after controlling for other confounding
factors. Although we are unable to comment on whether this
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Table 3. Relationship between calendar period, exposure to protease inhibitor (PI) and nonnucleoside reverse-transcriptase in-
hibitor (NNRTI) therapy, and the incidence of myocardial infarction, before and after adjustment for changes in risk factors for
cardiovascular disease.
Variable
Adjustment
Baseline risk
factors only
Changes
in non-lipid
risk factors
Changes
in non-lipid
risk factors
and lipid levels
Relative rate
(95% CI) P
Relative rate
(95% CI) P
Relative rate
(95%) CI) P
Relationship with combination antiretroviral therapy
Cumulative exposure to PIs (per year) 1.16 (1.11–1.21) !.001 1.15 (1.11–1.20) !.001 1.10 (1.05–1.16) !.001
Cumulative exposure to NNRTIs (per year) 1.05 (0.99–1.11) .09 1.04 (0.98–1.10) .19 1.03 (0.96–1.10) .39
Relationship with calendar period
1999–2000 1 1 1
2001 1.20 (0.84–1.71) .31 1.15 (0.81–1.64) .45 1.60 (0.97–2.65) .06
2002 0.84 (0.58–1.21) .34 0.75 (0.51–1.08) .12 1.11 (0.66–1.86) .69
2003 0.90 (0.62–1.29) .56 0.73 (0.50–1.05) .09 1.06 (0.63–1.77) .82
2004 0.83 (0.57–1.20) .32 0.64 (0.44–0.94) .02 1.02 (0.61–1.71) .95
2005–2006 0.50 (0.33–0.76) .001 0.36 (0.24–0.56) !.001 0.63 (0.36–1.09) .10
NOTE. Cumulative exposure to PIs and NNRTIs were both treated as time-updated covariates in all analyses. Fixed risk factors were male sex, HIV
exposure group, ethnicity, and cohort. Time-updated non-lipid covariates were age, body mass index (calculated as the weight in kilograms divided by the
square of the height in meters), family history of cardiovascular disease, smoking status, and a previous cardiovascular event. Time-updated lipid covariates
were cholesterol, high-density lipoprotein cholesterol, and triglyceride levels.
was a result of failure on the part of treating physicians to offer
these drugs in the first place or of refusal by the patient to
accept the drugs when offered, this highlights the importance
of assessing risk factors in all HIV-infected persons and en-
suring patient access to potentially beneficial interventions. It
should be noted that injection drug use (and other covariates
in our models, including risk factor and ethnicity) may also
act as a surrogate for socioeconomic status; this information
is not captured directly in the DAD study.
The proportion of patients undergoing invasive cardiovas-
cular procedures in the cohort increased over time, both among
those who had experienced a previous cardiovascular event and
among those who had not experienced such an event. However,
the correct interpretation of these findings is not clear. Although
the proportion of individuals who require invasive procedures
will likely increase as the risk of CVD among the cohort in-
creases, the use of these procedures as pre-emptive interven-
tions prior to the development of clinical CVD could become
more attractive, because expected survival of HIV-infected pa-
tients has improved.
We have not considered changes to antiretroviral therapy in
this analysis. However, it is recognized that some antiretroviral
drugs are associated with more-deleterious lipid profiles than
others [18–21], and switching antiretroviral regimens to those
perceived to be more “lipid friendly” has generally been as-
sociated with improvement in lipid parameters [22–24]. Pre-
liminary results from the DAD study have suggested that cli-
nicians are increasingly likely to make such changes [25];
further detailed analyses of these findings are ongoing.
The DAD study includes a large, geographically diverse, and
representative population of individuals with HIV infection
who are from clinics that encompass a wide variety of treatment
practices. To minimize bias, a number of standardized defi-
nitions for data collection have been introduced, and data qual-
ity checks are regularly performed. All cardiovascular events
and deaths are centrally validated to ensure that they meet the
stringent protocol-defined criteria.
A number of limitations of our study should be acknowl-
edged. First, in some cohorts, the date of starting lipid-lowering
therapy was estimated using the information available regarding
the use of these drugs at consecutive DAD study visits. Second,
information on changes in risk factors such as smoking may
have relied on a patient’s self-reported behavior. Although this
information has been collected since the start of the DAD study,
the quality of the information may have improved, which may
introduce bias. Similarly, because clinicians and patients have
become more aware of the relationship between cART and
CVD, information on some variables (e.g., family history of
CVD) may have been more actively sought, leading to a po-
tential apparent increase in such reports. Third, because in-
vestigators at sites participating in the DAD study are likely to
be particularly interested in CVD risk, they may have more
vigorously promoted risk reduction through behavioral and
therapeutic interventions; thus, changes in risk factors in this
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cohort may be greater than those elsewhere. Fourth, the DAD
study does not collect information regarding other behavioral
factors, such as diet and exercise, although any changes to these
factors would, to some extent, be reflected in changes to lipid
levels. Fifth, despite the rigorous procedures in the DAD study
to ensure that all end points are captured in a timely manner,
the possibility that our results regarding MI incidence may have
been affected by ascertainment bias must be considered, par-
ticularly in the most recent calendar period. It might be an-
ticipated that clinicians may be less likely to report MIs as the
study duration increases, contributing to an apparent decrease
in incidence over time; however, because all centers are visited
yearly and a substantial proportion of patients receiving follow-
up are monitored, we believe that the risk of this should be
minimal. Finally, because the DAD study is a closed cohort and
patient follow-up for the analysis of MI incidence is censored
after an individual develops an MI, there may be an artificial
reduction in the incidence of MI as those patients at highest
risk of MI drop out of the risk set.
In conclusion, our findings suggest that, although the CVD
risk profile among patients observed in the DAD study has
deteriorated since 1999, MI incidence rates have remained rel-
atively stable. This is possibly a result of a more aggressive
targeted approach to managing the risk of CVD.
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